Trials / Completed
CompletedNCT05867017
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 23 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.
Detailed description
The purpose of this research study is to understand the long-term effects of COVID-19 infection on individuals without any prior history of diabetes. This study will look at several measures of diabetes, such as glycemic control (blood glucose/sugar levels), function of beta cells (cells that make insulin to control sugar), insulin secretion and insulin sensitivity (fasting insulin levels). The following participants will be enrolled: 1) have had COVID-19 infection and were hospitalized and recovered, or 2) have had mild COVID-19 infection and were seen at outpatient clinics or ER and were not required to be hospitalized, or 3) have not had COVID-19 infection but were seen in outpatient clinics or ER during the same time period. The researchers hope to learn the long-term effects of COVID-19 infection in hospitalized patients. Specifically, they will be focusing on the subsequent development of diabetes and associated metabolic disturbances, such as impaired insulin secretion and insulin resistance. A relationship between COVID-19 and diabetes needs to be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Measure of physiologic parameters | Participants will have hepatic muscle and adipose tissue insulin sensitivity tested |
Timeline
- Start date
- 2023-07-10
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
- First posted
- 2023-05-19
- Last updated
- 2026-01-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05867017. Inclusion in this directory is not an endorsement.